A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS

Clinical Infectious Diseases

Volumn 62, Issue 2, 2016, Pages 258-261

  Hsu, Denise C ^a   Faldetta, Kimberly F ^a   Pei, Luxin ^a   Sheikh, Virginia ^a   Utay, Netanya S ^b   Roby, Gregg ^a   Rupert, Adam ^c   Fauci, Anthony S ^a   Sereti, Irini ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

immune reconstitution inflammatory syndrome; infliximab; mycobacterial infection

Indexed keywords

ATAZANAVIR; AZITHROMYCIN; COTRIMOXAZOLE; EFAVIRENZ; EMTRICITABINE; ETHAMBUTOL; GAMMA INTERFERON; INFLIXIMAB; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OCTREOTIDE; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; TENOFOVIR; TUMOR NECROSIS FACTOR; ANTIRETROVIRUS AGENT; IMMUNOLOGIC FACTOR;

ACID FAST BACTERIUM; ADD ON THERAPY; ADULT; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CERVICAL LYMPHADENOPATHY; CHYLOTHORAX; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOKINE PRODUCTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FEVER; FINE NEEDLE ASPIRATION BIOPSY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KNEE PAIN; LOW FAT DIET; LUNG LAVAGE; LUNG NODULE; MALE; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SWELLING; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; VIREMIA; WEIGHT REDUCTION; ADVERSE DRUG REACTION; HIV INFECTIONS; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGIC FACTORS; INFLIXIMAB; MALE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84960172014     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ841     Document Type: Article

References (15)

1. Namale PE, Abdullahi LH, Fine S, Kamkuemah M,Wilkinson RJ, Meintjes G. Paradoxical TB-IRIS in HIV-infected adults: A systematic review and meta-analysis. Future Microbiol 2015; 10:1077-99.
2. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J 2010; 36:1185-206.
3. Dorhoi A, Kaufmann SH. Tumor necrosis factor alpha in mycobacterial infection. Semin Immunol 2014; 26:203-9.
4. Sereti I, Rodger AJ, French MA. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS 2010; 5:504-10.
5. Mahnke YD, Greenwald JH, DerSimonian R, et al. Selective expansion of polyfunctional pathogen-specific CD4+ T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 2012; 119:3105-12.
6. Skerry C, Harper J, Klunk M, Bishai WR, Jain SK. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PloS One 2012; 7:e39680.
7. Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007; 45:1470-5.
8. Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 2005; 9:1057-8.
9. Garcia Vidal C, Garau J. Systemic steroid treatment of paradoxical upgrading reaction in patients with lymph node tuberculosis. Clin Infect Dis 2005; 41:915-6; author reply 6-7.
10. Jorge JH, Graciela C, Pablo AP, Luis SH. A life-threatening central nervous systemtuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis. J Clin Rheumatol 2012; 18:189-91.
11. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009; 48:1429-32.
12. O'Dowd C, Kewin P, Morris J, Cotton M. Tuberculosis complicated by immune reconstitution inflammatory syndrome in a patient on anti-TNFalpha therapy for Crohn's disease. BMJ Case Report 2011; doi:10.1136/bcr.09.2010.3376.
13. Lee HS, Lee Y, Lee SO, et al. Adalimumab treatment may replace or enhance the activity of steroids in steroid-refractory tuberculous meningitis. J Infect Chemother 2012; 18:555-7.
14. Blackmore TK, Manning L, Taylor WJ,Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008; 47:e83-5.
15. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18:257-64.